Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
BioXXmed financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€1.9
2024-10-10
Market Capitalization
€138.7 K
2024-10-10
Revenue
€3 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.0K | 36.0K | 36.0K | 45.0K | 12.0K | 17.0K | 3.0K |
| Gross profit | 3.0K | 37.0K | 40.0K | 52.0K | 12.0K | 20.0K | 34.0K |
| Gross profit margin, % | 102.8% | 111.1% | 115.6% | 100.0% | 117.6% | 1133.3% | |
| Operating expense total | 1.2M | 1.2M | 1.9M | 1.5M | 830.0K | 866.0K | 906.0K |
| Depreciation and amortization | 30.0K | 19.0K | 21.0K | 59.0K | 5.0K | ||
| EBITDA | (1.2M) | (1.2M) | (1.8M) | (1.5M) | (818.0K) | (846.0K) | (872.0K) |
| EBITDA margin, % | -3211.1% | -5047.2% | -3268.9% | -6816.7% | -4976.5% | -29066.7% | |
| EBIT | (1.2M) | (1.2M) | (1.8M) | (1.5M) | (823.0K) | (846.0K) | (869.0K) |
| EBIT margin, % | -3263.9% | -5105.6% | -3400.0% | -6858.3% | -4976.5% | -28966.7% | |
| Interest income | 53.0K | 2.0K | 35.0K | 15.0K | |||
| Interest expense | 251.0K | 100.0K | 1.0K | 2.0K | 42.0K | ||
| Pre tax profit | (1.4M) | (1.3M) | (1.8M) | (4.0M) | (830.0K) | (21.0M) | (997.0K) |
| Income tax expense | 1.0K | 40.0K | (40.0K) | ||||
| Net Income | (1.4M) | (1.3M) | (1.8M) | (4.1M) | (830.0K) | (20.9M) | (997.0K) |